Background Human immunodeficiency virus (HIV) infection is the strongest risk factor for
developing tuberculosis and has fuelled its resurgence, especially in sub-Saharan Africa. In …

Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet
tuberculosis series provided a comprehensive overview of global control efforts and …

This brief, inexpensive guide introduces students and novices to the key elements of
qualitative research methods. Written in a friendly, conversational style, replete with good …

Background In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)–
associated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to assess …

All members of the Guidelines Group were asked to complete a World Health Organization
(WHO) declaration of interest form and only two declared a conflict of interest. These were …

Background Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more
common in people with HIV than in people without HIV. We aimed to assess the effect of …

Background In accordance with WHO guidelines, people with HIV infection in Botswana
receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin …

Objective: To determine whether interferon-gamma release assays (IGRAs) improve the
identification of HIV-infected individuals who could benefit from latent tuberculosis infection …

The human immunodeficiency virus (HIV) pandemic presents a significant challenge to
global tuberculosis (TB) control. TB is a leading preventable cause of death among people …

Background Temprano ANRS 12136 was a factorial 2× 2 trial that assessed the benefits of
early antiretroviral therapy (ART; ie, in patients who had not reached the CD4 cell count …